Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius soars on second quarter revenue beat
- SunEdison (SUNE) Misses Q2 EPS by 52c
- BrainsWay Ltd. (BWAY) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
